Little Green Pharma Ltd
ASX:LGP
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Little Green Pharma Ltd
Little Green Pharma Ltd. produces medicinal cannabis products for sale to Australian patients. The company is headquartered in Perth, Western Australia. The company went IPO on 2020-02-20. The Company’s products includes LGP Classic range and LGP Flower range. Its LGP Classic range includes tetrahydrocannabinol (THC) and cannabidiol (CBD) ratios presented in an oil formulation. Its LGP Flower range is grown and manufactured in the Southwest of Western Australia and supplied as dried medicinal cannabis whole flowers. The firm supplies medical-grade cannabis products to Australian, European and overseas markets. The company is also engaged in promoting education and outreach programs.
Little Green Pharma Ltd. produces medicinal cannabis products for sale to Australian patients. The company is headquartered in Perth, Western Australia. The company went IPO on 2020-02-20. The Company’s products includes LGP Classic range and LGP Flower range. Its LGP Classic range includes tetrahydrocannabinol (THC) and cannabidiol (CBD) ratios presented in an oil formulation. Its LGP Flower range is grown and manufactured in the Southwest of Western Australia and supplied as dried medicinal cannabis whole flowers. The firm supplies medical-grade cannabis products to Australian, European and overseas markets. The company is also engaged in promoting education and outreach programs.
Revenue Growth: Little Green Pharma reported revenue of over $10.1 million for the quarter, representing a rise of more than 10% from the prior period, mainly driven by strong flower sales in Australia and steady demand in Europe.
Australian Rebound: After several quarters of decline, Australian market revenue increased, reflecting successful strategies to regain market share.
European Expansion: The company continues to see growth in Europe, highlighted by successful launches and strong sales in the U.K. and early traction for the CherryCo brand in Germany.
Cost Efficiency: Recent automation, offshoring, and voluntary redundancies are expected to result in $0.5 million in annual savings, aiming to support margins and profit.
Regulatory Positioning: LGP is well positioned for upcoming regulatory changes in both Australia and Europe, with its compliance-focused operations expected to benefit from higher industry standards.
Denmark as a Hub: The Denmark facility has been scaled to 10 tonnes and is being positioned as a potential processing hub for the wider European market.
Strong Balance Sheet: The company maintains a solid net tangible asset position over $70 million, minimal debt, and $2.3 million in cash, supporting its growth strategy and giving it flexibility for consolidation opportunities.
